Melanoma Institute Australia

This study is testing a combination of two immunotherapy drugs (nivolumab and relatlimab) given to patients before surgery for Merkel cell carcinoma, a rare and aggressive skin cancer. The goal is to see if this 'pre-surgery' treatment can shrink or eliminate the tumor and, most …

This study is testing if combining two standard cancer treatments works better than one alone for advanced melanoma that has spread to a few places in the body. It will compare standard immunotherapy drugs, which help the body's immune system fight cancer, to those same drugs plu…

This trial is testing new combinations of immunotherapy drugs given before surgery for patients with advanced melanoma who are predicted to respond poorly to standard treatments. The study involves 494 patients with stage 3 skin melanoma or mucosal melanoma that can be surgically…

This study is testing if adding a precise form of brain radiation to a two-drug immunotherapy combination works better than the immunotherapy alone. It is for adults with melanoma skin cancer that has spread to the brain but is not yet causing symptoms. The main goal is to see if…

This study is testing whether giving two immunotherapy drugs before surgery can better shrink advanced skin cancer tumors and help prevent the cancer from coming back. It will involve 20 adults with a type of skin cancer called cutaneous squamous cell carcinoma that is advanced b…

This study is testing if a smaller surgery is as good as the standard, larger surgery for people with stage III melanoma that has spread to lymph nodes. After 6 weeks of immunotherapy, participants will be randomly assigned to have either just the main affected lymph node removed…

This study is testing a new predictive tool to see if it can accurately forecast which patients with melanoma and other cancers will respond to immunotherapy drugs. It will involve 1,000 patients who are eligible for standard immunotherapy treatment. The goal is to see if this to…